SiteOne Landscape Supply (NYSE:SITE) reported quarterly sales of $1.22 billion which missed the analyst consensus estimate of $1.24 billion by 1.61 percent. This is a 12.55 percent increase over sales of $1.08 billion the same period last year.
Pulmatrix Announces Submission Of IND Application To FDA To Initiate A Phase 2 Trial Of Investigational Drug PUR3100 To Treat Acute Migraine
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous
